MarketCap
Facebook
X
TelegramQuarterly report 2025-Q1
added 04-22-2025
Danaher Corporation Net Debt 2011-2025 | DHR
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Danaher Corporation
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 13.6 B | 11 B | 13.3 B | 19.8 B | -5.84 B | 1.82 B | 8.95 B | 9.89 B | 11.3 B | 12.1 B | 468 M | 384 M | 3.66 B | 4.77 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.8 B | -5.84 B | 7.51 B |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
-6.88 M | $ 19.06 | -1.6 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-76 M | $ 20.31 | -5.8 % | $ 221 M |  China |
 |
Co-Diagnostics
CODX
|
-11.9 M | $ 0.23 | -4.17 % | $ 6.75 M | USA |
 |
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
-108 M | $ 39.2 | -0.49 % | $ 1.09 B | USA |
 |
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.36 | 3.19 % | $ 294 M | Israel |
 |
BioNano Genomics
BNGO
|
-2.64 M | $ 1.51 | -0.9 % | $ 1.92 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M |  Britain |
 |
Exact Sciences Corporation
EXAS
|
-560 M | $ 101.86 | 0.28 % | $ 18.9 B | USA |
 |
DexCom
DXCM
|
-487 M | $ 67.65 | 0.12 % | $ 26.1 B | USA |
 |
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | USA |
 |
Fulgent Genetics
FLGT
|
-53.3 M | $ 26.63 | -0.34 % | $ 805 M | USA |
 |
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | China |
 |
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
-48 M | $ 19.19 | -1.49 % | $ 1.03 B | USA |
 |
Celcuity
CELC
|
82.8 M | $ 101.0 | -1.22 % | $ 3.98 B | USA |
 |
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | USA |
 |
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.19 | -0.31 % | $ 102 K | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
11.2 B | $ 227.26 | 0.15 % | $ 41.2 B | USA |
 |
Guardant Health
GH
|
646 M | $ 100.93 | -1.99 % | $ 12.4 B | USA |
 |
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | USA |
 |
Myriad Genetics
MYGN
|
115 M | $ 6.32 | -2.55 % | $ 573 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-4.37 M | $ 4.75 | -4.81 % | $ 2.55 M | USA |
 |
Neogen Corporation
NEOG
|
751 M | $ 7.2 | 0.98 % | $ 1.56 B | USA |
 |
National Research Corporation
NRC
|
30.1 M | $ 18.95 | 1.55 % | $ 465 M | USA |
 |
Illumina
ILMN
|
-494 M | $ 134.56 | -0.29 % | $ 21.4 B | USA |
 |
Charles River Laboratories International
CRL
|
2.1 B | $ 203.33 | -0.11 % | $ 10.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 175.36 | -0.34 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
14.5 M | $ 6.79 | -0.44 % | $ 880 M | USA |
 |
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | Israel |
 |
Koninklijke Philips N.V.
PHG
|
2.48 B | $ 27.26 | 0.57 % | $ 20 B |  Niderland |
 |
Laboratory Corporation of America Holdings
LH
|
4 B | $ 252.95 | -0.4 % | $ 21.2 B | USA |
 |
ICON Public Limited Company
ICLR
|
4.63 B | $ 182.75 | -0.05 % | $ 15.1 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
183 M | $ 685.99 | -0.36 % | $ 56.6 B | USA |
 |
Lantheus Holdings
LNTH
|
-346 M | $ 67.0 | 0.43 % | $ 4.64 B | USA |
 |
Personalis
PSNL
|
-48.8 M | $ 8.01 | -1.6 % | $ 475 M | USA |
 |
Mettler-Toledo International
MTD
|
1.8 B | $ 1 419.41 | -0.06 % | $ 30.1 B |  Schweiz |
 |
Agilent Technologies
A
|
1.24 B | $ 138.09 | -0.22 % | $ 42 B | USA |
 |
Quidel Corporation
QDEL
|
-377 M | $ 29.27 | -0.12 % | $ 1.23 B | USA |
 |
Biomerica
BMRA
|
-1.94 M | $ 2.6 | -3.7 % | $ 5.97 M | USA |